Oral mucositis (OM) is a frequent complication of myeloablative therapy and HSCT. We evaluated the feasibility, reliability, and validity of a new patient selfreported daily questionnaire on OM and its impact on daily functions. This OM Daily Questionnaire (OMDQ), containing 10 items, was developed for use in palifermin clinical trials. In a phase 3 study, 212 patients received palifermin or placebo for three consecutive days before conditioning and three consecutive days after HSCT. Compliance rates were consistently 480% for most patients. Mouth and throat soreness (MTS) and MTSActivity Limitations (MTS-AL) (swallowing, drinking, eating, talking, and sleeping) scores on consecutive days were highly correlated (days 7,8 ¼ 0.70-0.86; test-retest reliability). Correlations among items measuring the same construct ranged between 0.5 and 0.8 (internal consistency reliability). The WHO Oral Toxicity scale was the clinical comparator to assess the criterion, discriminative, and evaluative validities of MTS-related questions. Most correlation coefficients between the WHO and MTS ranged between 0.45 and 0.55. Patients with more severe WHO OM grades had higher MTS mean scores. Changes in MTS scores were similar, but patients detected changes 1-3 days earlier than clinicians. In conclusion, the OMDQ is a feasible, reliable, valid, and responsive patient-reported measure of OM severity.
Introduction
Oral mucositis (OM) is among the most debilitating of side effects in cancer patients receiving myeloablative therapy prior to bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT). 1 Almost all patients experience some degree of OM after myeloablative therapy and BMT and approximately 75% have oral ulcers within 3-5 days after BMT. [2] [3] [4] OM is a result of a complex cascade of physiological events. 5 Damage from radiotherapy and chemotherapy to the rapidly dividing tissues that comprise the mucosal epithelium of the mouth and throat is followed by upregulation of transcription factors and proinflammatory cytokines in the submucosa, in turn leading to oral ulceration. OM can negatively impact upon all aspects of quality of life (physical, emotional, social, and functional). 6 Severe pain from OM can make basic daily activities such as eating, talking, swallowing, and sleeping difficult or impossible. It has been recommended that clinical trials of new interventions for OM should include objective assessment of patient-reported outcomes. 7 As shown in Table 1 , there are several established instruments for the clinical assessment of OM severity, including scales from the World Health Organization (WHO), the Radiation Therapy Oncology Group (RTOG), and the Western Consortium for Cancer Nursing Research (WCCNR), among others. [8] [9] [10] [11] [12] [13] Currently, there is no established patient reported questionnaire with demonstrated reliability and validity for patient self-assessment of the signs and symptoms of OM.
Until recently, there have been no approved agents to reduce the incidence and/or duration of OM. Palifermin (Kepivancet) is a truncated, recombinant human form of keratinocyte growth factor (rHuKGF) that was found to help protect mucosal tissue against the damaging effects of irradiation in animal studies. 14 In 2004, the US FDA approved palifermin to decrease the incidence and duration of severe OM in patients with hematologic malignancies receiving myelotoxic therapy requiring HSC support. The safety and efficacy of palifermin have not been established in patients with nonhematologic malignancies. As part of the clinical development program for palifermin, a daily questionnaire called the Oral Mucositis Daily Questionnaire (OMDQ) was created to record patient-reported outcomes of OM on a daily basis without requiring clinic visits. It was developed through a series of focus groups and one-on-one interviews with cancer patients and was later refined after preliminary versions were used in phase 1 and 2 trials of palifermin. 7 An objective of this study was to evaluate and confirm the psychometric properties (feasibility, reliability, validity, and responsiveness) of the patient-reported OMDQ. We also compared the OMDQ results with those results from established clinical scales rated by clinicians in this pivotal phase 3 clinical trial of palifermin. 15 
Patients and methods
The data for this psychometric assessment came from a randomized, placebo-controlled, double-blind phase 3 trial for which the primary methods and results were described previously. 15 This study was designed to evaluate the efficacy and safety of palifermin in reducing the duration and severity of OM and its sequelae (soreness of the mouth and throat, use of opioid analgesics, total parenteral nutrition, and infections) in patients with hematologic cancers undergoing autologous HSCT after receiving totalbody irradiation (TBI) and high-dose chemotherapy. Adults 18 years of age or older who were scheduled to receive TBI and high-dose chemotherapy followed by autologous HSCT (study day 0) were eligible for the study. Patients had to have a diagnosis of non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), or multiple myeloma (MM). All patients were required to have a Karnofsky performance score of 70% or greater and a minimum of 1.5 Â 10 6 CD34 þ cells/kg cryopreserved for infusion. Patients received intravenous (i.v.) boluses of palifermin (60 mg/kg/ day) or placebo for three consecutive days prior to the conditioning regimen (TBI þ etoposide þ cyclophosphamide) and three consecutive days after autologous HSCT.
Oral mucosa assessment of patients was performed daily using the WHO, RTOG, and WCCNR scales from day À8 before transplantation until day 28 after transplantation, or until the OM had resolved to WHO grade 0-2. If the patient was discharged prior to day 28, outpatient study visits for oral mucosa assessments occurred on days 4, 7, 14, 21, and 28. All patients used a daily diary to complete the OMDQ, without assistance, from day À12 through the final follow-up visit at day 28 in the inpatient and outpatient settings.
Oral mucositis daily questionnaire
The OMDQ was developed as a mucositis-specific questionnaire to assess patient-reported outcomes and was based on a series of focus groups and one-on-one interviews with cancer patients. 7 Early versions of the OMDQ were administered in phase 1 clinical trials (both in hematological and solid tumor settings) receiving high-dose BEAM and 5-FU/Leucovorin treatment regimens. Results from these studies showed that the OMDQ correlated positively with clinically measured assessments of OM (r ¼ 0.2-0.5 for the MTS vs RTOG comparisons; unpublished data). After the initial version of the OMDQ was tested in a phase 1 study of palifermin in the HSCT setting, extensive item reduction analyses resulted in a final 6-question version (10 total items: seven on OM and its impact on daily functioning, two on diarrhea, and one on overall health; Figure 1 ). This shortened version was used in subsequent trials, including this phase 3 pivotal trial (Stiff et al., in press). Further validation studies administering similar versions of the OMDQ are ongoing in the head and neck cancer as well as other solid tumor disease settings (manuscript in preparation). The solid tumor version of the OMDQ has the same MTS items; however, the diarrhea items were either modified or replaced to be more sensitive in measuring the symptoms intrinsic to each solid tumor setting. For most questions in the OMDQ, a higher score indicated a worsening in symptom severity or more interference with functional activity. For the question pertaining to overall health, a higher score indicates better overall health status. The questionnaire also includes a skip pattern: patients who responded with a 0 to the mouth and throat soreness (MTS) Question 2 (Q2) were instructed to skip the MTS-Activity Limitation (MTS-AL) questions (Q3a-3e) and the Overall MTS Q4. Likewise, patients who responded with a 0 to the Diarrhea Q5 were instructed to skip the Overall Diarrhea Q6.
Psychometric assessments and statistical methods
Psychometric properties evaluated in this study included feasibility; test-retest and internal consistency reliabilities; and criterion, discriminative, and evaluative validities (responsiveness). Feasibility was assessed using both daily and longitudinal compliance rates. The daily compliance rate was calculated for each question of the OMDQ and was reported as the proportion of eligible patients who completed the question on the specified day. As a result of the skip pattern, compliance rate calculations included imputed values of 0 for Q3 and Q4 for patients who responded with a 0 to MTS Q2 and answered Q5. The same methodology was applied for Q6 when patients responded with a 0 to Q5. Longitudinal compliance was assessed by calculating the proportion of patients who completed at least 80% of their assessments (41 maximum assessments) over the entire study period (day À12 to day 28) for each question of the OMDQ and was conducted to complement the daily compliance rate analysis.
For test-retest reliability, Pearson correlation coefficients were calculated on paired study days 13 and 14 and days 27 and 28 for each OMDQ question. These study days were chosen for analysis because patients' OM should have subsided by these days and day-to-day variation was not expected to be significant. The internal consistency reliability of the OMDQ was evaluated by calculating the Pearson's correlation coefficients between each pair of questions on days 7, 10, and 14.
Criterion validity was evaluated by calculating the Pearson correlation coefficients between the MTS-related question scores (Q2, Q3a-3e, Q4) and the WHO, RTOG, and WCCNR scores on days 7, 10, and 14. The discriminative validity was evaluated by comparing the mean MTS-related scores between patients with severe (WHO grades 3 or 4) OM and those with mild (WHO grades 1 or 2) OM on days 7 and 14. Effect sizes (the difference between the means/common s.d.) were also calculated for mild OM (WHO grades 1 or 2) vs severe OM (WHO grades 3 or 4) groups and comparisons were made to provide an indication of the clinically significant differences between the two groups. 16, 17 The evaluative validity (responsiveness) was based on Pearson correlation coefficients calculated between changes in the MTS-related scores and changes in the clinical scales from days 7 to 14. Mean daily scores for the WHO, RTOG, and WCCNR scales and the Q2 of the OMDQ were plotted over time for visual comparison. The lag time (beginning on day À8) between the first report of a score of 2, 3, or 4 for Q2 and the first report of the same WHO grade of OM was categorized as 43 days earlier, 1-3 days earlier, same day, 1-3 days later, or 43 days later.
Data for psychometric and statistical analyses were drawn from the pooled patient population (n ¼ 212), with the analyses of each individual question based on data from patients who completed that question. Statistical analyses were performed using SAS Version 8.2 (SAS Institute, Cary, NC).
Results
A total of 212 patients received at least 1 dose of palifermin (n ¼ 106) or placebo (n ¼ 106). Most patients were male (62%) and white (74%), with patient age ranging from 18 to 69 years (median ¼ 49 years). The majority of patients had a Karnofsky performance status of X90 and had received prior chemotherapy. The most common diagnoses were NHL (67%) and Hodgkin's disease (21%).
Feasibility
Patients completed 87% of the scheduled daily assessments of MTS over the entire study period. For each question in the OMDQ, at least 78% of all patients completed X80% of the questions daily (range ¼ 78-82%). The lowest daily compliance rate was for Q2 at 80%, with compliance ranging from 82 to 95% during the pre-HSCT period (days À11 to À1); from 80 to 95% between days 0-14 (period with most common occurrences of mucositis); and from 81 to 89% between day 15 and the end of study. Mean overall compliance rates for the remaining questions of the OMDQ ranged from 85 to 87% and their daily compliance rates were similar to that observed with Q2.
Test-retest reliability of the OMDQ Test-retest reliability coefficients of 0.7-0.9 are considered acceptable for early stages of predictive or construct validation research. 18 The test-retest correlation coefficients between consecutive days for the MTS-related questions (Q2, Q3a-3e, Q4) ranged from 0.75 to 0.95 (Table 2) . Lower correlations were observed during periods when OM severity was expected to change on a daily basis, and higher correlations were usually observed after OM manifestations had subsided. For example, the correlation for Q2 was 0.86 between days 13 and 14 and 0.94 between days 27 and 28. Among the MTS-related questions, Q3e (sleeping) had the lowest test-retest reliability at 0.75. For Q1, Q5, and Q6 (overall health and diarrhea questions), the test-retest reliabilities were also somewhat lower at 0.76, 0.58, and 0.64, respectively.
Internal consistency reliability
The correlations between scores for items measuring the same or similar constructs (i.e., all MTS-related scores and all diarrhea-related scores) were much higher than between scores for items measuring different constructs (i.e., between MTS (Q2) and diarrhea (Q5)). Interestingly, the lowest correlation was seen between Q3e (sleeping) and the other MTS-related questions, suggesting that the sleeping item may not belong to the same construct that is related to the limitations of mouth and throat-related functioning.
The correlation coefficients for all questions at day 7 are shown in Table 3 . The magnitudes of these correlation coefficients were similar at the other study days for which internal consistency was evaluated (days 10 and 14).
Criterion validity
The criterion validity of the MTS-related questions (Q2, Q3a-3e, Q4) was evaluated by comparing their scores to the results of the WHO, RTOG, and WCCNR scales at days 7 and 14 ( Table 4 ). The correlations were strongest between the MTS-related and WHO scale results, ranging from 0.30 to 0.55 on day 7 and from 0.25 to 0.49 on day 14 (the lowest correlations being for sleeping (Q3e) at both study days).
Correlations between the MTS-related scores and the RTOG and WCCNR scales were generally weaker than those for the WHO scale.
Discriminative validity
Mean scores on the MTS-related questions (Q2, Q3a-3e, Q4) were significantly higher (indicating greater mouth and throat pain and limitations on daily activity) among patients with severe OM (WHO grade 3 or 4) than among patients with mild OM (WHO grade 1 or 2) on day 7 (Table 5) . For example, patients with WHO grade 1 or 2 OM on day 7 averaged scores of 2.1, 1.6, and 2.3, respectively, for Q2 (MTS), Q3a (swallowing), and Q3c (eating) while patients with WHO grade 3 or 4 OM had average scores of 2.9, 2.7, and 3.4, respectively, for the same questions. The mean scores for these same questions were also higher (but at a lesser magnitude of difference) among patients with WHO grade 3 or 4 OM at day 14. Effect sizes of 0.2-0.5 are considered minimally important in the measurement of patient-reported outcomes and the observed effect sizes for all MTS-related questions ranged from 0.52 to 1.0 on day 7 and 0.33-0.57 on day 14.
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Evaluative validity (responsiveness) Correlations between the change in scores for MTS-related questions and the change in WHO grades from days 7 to 14 ranged from 0.28 to 0.33 except for Q3e (sleeping) at 0.08 (Table 6 ). The correlations were lower between the MTS-related scores and the RTOG and WCCNR scales, especially for Q3e (sleeping) and Q4 (Overall MTS). As shown in Figure 2 , patient-reported scores for MTS and assessments reported by clinicians using the WHO, RTOG, and WCCNR scales followed similar patterns over time. Using the MTS Q2, patients were able to detect changes in their OM symptoms earlier, often by 1-3 days, than trained clinicians who assessed OM severity based on the clinical scales (WHO, RTOG, and WCCNR). Thus, patients reported the most severe symptoms of OM on day 5 while clinicians did not report the worst cases of OM until day 7. As shown in Table 7 , 67, 68, and 58% of patients using Q2 reported Table 3 Internal consistency reliability: correlation between oral mucositis daily questionnaire questions on study day 7 grade 2, 3, or 4 OM, respectively, at least 1 day earlier than clinical personnel using the WHO scale. In contrast, only 23, 13, and 27% of patients reported grade 2, 3, or 4 OM, respectively, at least 1 day later than the caregiver or physician. This apparent lag time may be the reason for the relatively low correlation coefficients between the change in MTS scores and the change in the WHO grades. 
Discussion
These patient-reported outcome results from the pivotal phase 3 trial provide strong support for the overall reliability, validity, and responsiveness of the OMDQ. 15 Patient compliance rates ranged from 80 to 95% during the first 2 weeks after TBI, intensive high-dose chemotherapy, and HSCT, indicating that the OMDQ is a feasible tool for self-monitoring of changes in OM severity by cancer patients. The test-retest reliability measures for MTSrelated questions were above the acceptable level. Internal consistency reliability measures demonstrated correlations among the MTS-related questions (Q2, Q3a-3e, and Q4) were higher than those between the MTS-related and other questions (Q1, Q5, and Q6) dealing with overall health and diarrhea. Interestingly, the correlation for Q3e (sleeping) was not as strong as the other MTS-related questions. This finding is consistent with a previous report that OM has more variable effects on the affective components of pain than on the sensory components. 19 Additionally, this result might indicate that sleep patterns are influenced by other factors and not just by OM and its clinical manifestations.
Of the three clinical scales for OM in this study, the WHO results had the strongest associations with the OMDQ, particularly in terms of the MTS-related components, suggesting that the WHO scale may be the best clinical measure of OM in the HSCT setting. This result is not unexpected, given the nature of the three clinical scales. The RTOG and WCCNR scales are based solely on objective assessments of physiological changes of the oral cavity, while the WHO scale is a combination of both objective assessments of the oral cavity and subjective assessments of the condition of the patient. Thus, the WHO scale may be able to detect nonvisible symptoms such as pharyngeal mucositis that are not detectable by the RTOG and WCCNR scales. Significant correlations were seen between the MTS-related scores and the WHO scale. Most of the MTS-related scores were higher (indicating more pain and activity limitations) for patients with severe OM (WHO grade 3 or 4) compared to patients with mild OM (WHO grade 1 or 2). Changes in the MTS-related scores paralleled the changes observed with the WHO scale, demonstrating the evaluative validity or responsiveness of these questions. In addition to the WHO, several other scales are also available for the clinical assessment of MTS, including the scales from RTOG and WCCNR that were used in this study. [9] [10] [11] [12] [13] While most clinical assessment scales require a clinic visit and assessment by trained clinical personnel, the OMDQ can be completed by patients on a daily basis without clinician assistance. As a result, the OMDQ can be used in clinical settings to monitor day-to-day changes in the severity and impact of OM that otherwise may go undetected. The potential benefit of the OMDQ was clearly demonstrated by the early detection of changes in OM severity by MTS Q2. Patient-reported scores of OM severity peaked around day 5 while scores measured using the WHO, RTOG, and WCCNR scales did not peak until day 7, both of which are consistent with previous longitudinal studies of the time course of OM after HSCT. 2, 4 Significantly, patients using the OMDQ often detected changes in and progression of OM severity 1-3 days earlier than clinical personnel who used the WHO scale. These results strongly suggest that the MTS components of the OMDQ may enable earlier detection of OM and may lead to changes in therapy, including earlier initiation of analgesics. 7 Further evaluation of this OMDQ in other clinical settings involving OM is ongoing.
The results of the questions related to diarrhea (Q5 and Q6) showed minimal correlation between this side effect and OM. In this patient population, there is wide variation in the administration of treatments known to cause diarrhea, such as antibiotics and high caloric supplements. Additionally, these patients often have an increased risk of opportunistic infections (e.g., Clostridium difficile) causing diarrhea. These factors likely contributed to the findings in this study. Thus, diarrhea may not be an appropriate clinical indicator of OM progression in the autologous HSCT setting.
In summary, mouth and throat pain and limitations on daily functions due to OM are common and debilitating consequences of myeloablative therapy followed by HSCT. Previously, no established PRO instrument had demonstrated reliability and validity for patients' self-assessment of OM. The MTS-related questions of the OMDQ are valid, reliable, and responsive measures of OM severity that can be completed by patients on a daily basis in order to obtain more timely observations of OM's clinical progression. These questions provide a simple method for selfassessment of mouth and throat pain and are at least as effective as validated clinical assessment tools currently in use by clinicians. Furthermore, the daily use of the OMDQ in addition to periodic clinical assessment may enable clinicians to identify and manage OM more rapidly and identify improvements with investigational agents more precisely.
